Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients by unknown
Liu et al. Chin J Cancer  (2017) 36:12 
DOI 10.1186/s40880-016-0175-2
ORIGINAL ARTICLE
Association between DNA mismatch 
repair gene polymorphisms and platinum-based 
chemotherapy toxicity in non-small cell lung 
cancer patients
Jun‑Yan Liu1, Chen‑Yue Qian2,3,4, Yuan‑Feng Gao2,3,4, Juan Chen2,3,4, Hong‑Hao Zhou2,3,4 and Ji‑Ye Yin2,3,4*
Abstract 
Background: Chemotherapy toxicity is a serious problem from which non‑small cell lung cancer (NSCLC) patients 
suffer. The mismatch repair (MMR) system is associated with platinum‑based chemotherapy toxicity in NSCLC patients. 
In this study, we aimed to investigate the relationship between genetic polymorphisms in the MMR pathway and 
platinum‑based chemotherapy toxicity in NSCLC patients.
Methods: A total of 220 Chinese lung cancer patients who received at least two cycles of platinum‑based chemo‑
therapy were recruited for this study. Toxicity was evaluated in each patient after two cycles of chemotherapy. A total 
of 44 single nucleotide polymorphisms were selected to investigate their associations with platinum‑based chemo‑
therapy toxicity.
Results: MutS homolog 2 (MSH2) rs6544991 [odds ratio (OR) 2.98, 95% confidence interval (CI) 1.20–7.40, P = 0.019] 
was associated with gastrointestinal toxicity in the dominant model; MSH3 rs6151627 (OR 2.38, 95% CI 1.23–4.60, 
P = 0.010), rs6151670 (OR 2.05, 95% CI 1.07–3.93, P = 0.031), and rs7709909 (OR 2.38, 95% CI 1.23–4.64, P = 0.010) 
were associated with hematologic toxicity in the dominant model. Additionally, MSH5 rs805304 was significantly asso‑
ciated with overall toxicity (OR 2.21, 95% CI 1.19–4.09, P = 0.012), and MSH5 rs707939 was significantly associated with 
both overall toxicity (OR 0.42, 95% CI 0.23–0.76, P = 0.004) and gastrointestinal toxicity (OR 0.44, 95% CI 0.20–0.96, 
P = 0.038) in the dominant model.
Conclusion: Genetic polymorphisms in the MMR pathway are potential clinical markers for predicting chemotherapy 
toxicity in NSCLC patients.
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Background
Non-small cell lung cancer (NSCLC) is a common can-
cer and the main cause of cancer-related mortality world-
wide [1–5]. Although many new target drugs, such as 
gefitinib and erlotinib, have been used to treat NSCLC, 
cytotoxic drugs, such as platinum, are still used as first-
line agents in the treatment of NSCLC [6, 7]. However, 
adverse drug reactions, such as nephrotoxicity, hepato-
toxicity, hematologic toxicity, and gastrointestinal toxic-
ity, are major obstacles to successful treatment [8–10]. 
Thus, it is important to identify biomarkers that can be 
used to predict platinum-based chemotherapeutic toxic-
ity [11].
DNA mismatch repair (MMR) is a key DNA repair sys-
tem [12, 13]. It is highly conserved and plays an important 
role in correcting errors generated during DNA replica-
tion [14, 15]. MMR proteins interact with one another to 
form protein complexes that recognize and digest mis-
matched DNA segments and ultimately fill mismatch 
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gaps [16]. Briefly, MutL homolog 1 (MLH1) dimer-
izes with postmeiotic segregation increased 1 (PMS1), 
PMS2, or MLH3 to form the MLH1/PMS2 (MutLα), 
MLH1/PMS1 (MutLβ), or MLH1/MLH3 (MutLγ) het-
erodimer and MutS homolog 2 (MSH2) dimerizes with 
MSH6 or MSH3 to form the MSH2/MSH6 (MutSα) or 
MSH2/MSH3 (MutSβ) heterodimer so as to bind the 
DNA helix and recognize DNA mismatches. Together 
with the abovementioned MutL complexes, the MutSα 
complex guides the repair of single-base and small-loop 
mismatches, whereas the MutSβ complex guides the 
repair of small- to large-loop mismatches [16–19]. Thus, 
MutSα and MutLα are key proteins in the MMR system 
and are responsible for mismatch detection and subse-
quent repair event coordination [20, 21].
There are several partially overlapping DNA repair 
pathways, including base excision repair (BER), nucleo-
tide excision repair (NER), double-strand break repair 
(DSBR), and MMR [22]. A previous study showed that 
mutations in DNA repair genes affect the effectiveness 
and toxicity of platinum-based chemotherapy in NSCLC 
patients [23]. MMR plays a key role in maintaining 
genomic stability through the highly conserved biological 
pathway. It is an important determinant of platinum cel-
lular toxicity. The formation of platinum/DNA adducts 
blocks replication and transcription of DNA, and the 
MMR system plays an important role in removing these 
adducts. MMR defects lead to replication and recom-
bination errors and cause 6-thioguanine (6-TG)- and 
O6-methylguanine-induced toxicity in DNA glycosylase-
deficient cells [24]. It has been reported that mutations in 
MMR pathway genes may be associated with platinum-
based chemotherapy toxicity in NSCLC patients [23, 25]. 
In addition, mutations in MMR genes, particularly those 
in MSH3 and MSH5, may be associated with the risk of 
lung cancer and even lead to increased alkylation toler-
ance [26].
Our previous studies showed that genetic polymor-
phisms were useful clinical markers for chemotherapy 
response and toxicity prediction in lung cancer patients 
[9, 27–29]. To investigate the relationship between MMR 
pathway genetic polymorphisms and platinum-induced 
toxicity, we evaluated 6 MMR genes (MLH1, MSH2, 




All patients met the following inclusion criteria were 
selected: (1) patients between 18 and 80  years old; (2) 
patients newly diagnosed with NSCLC, including adeno-
carcinoma or squamous cell carcinoma, with histologi-
cal or cytological examination at the Affiliated Cancer 
Hospital or Xiangya Hospital of Central South University 
(Changsha, Hunan, China) between December 2012 and 
December 2015; (3) patients who received at least two 
cycles of platinum-based chemotherapy, e.g., cisplatin 
or carboplatin chemotherapy; (4) patients with no his-
tory of chemotherapy or radiotherapy; and (5) patients 
with no history of surgery before or during chemother-
apy. Patients with active infections or other concomitant 
malignancies were excluded.
All patients provided written informed consent before 
they participated in this study. The study protocol was 
approved by the Ethics Committee of Xiangya School 
of Medicine, Central South University (approval num-
ber: CTXY-110008-1). This clinical research project was 
approved by the Chinese Clinical Trial Registry under the 
following registration number: ChiCTR-RNC-12002892 
(http://www.chictr.org/cn/).
SNP selection, DNA extraction, and genotyping
All single nucleotide polymorphisms (SNPs) were 
selected by Haploview (Broad Institute, Cambridge, MA, 
USA) using pair-wise tagging with default settings (pair-
wise r2 threshold = 0.8). The following SNPs were eligi-
ble for further study: SNPs with a minor allele frequency 
(MAF) ≥ 5% in the Han Chinese population and SNPs in 
Hardy–Weinberg equilibrium (HWE) (P > 0.05).
All blood samples were collected in the morning and 
stored at −20°C for 4  h. Genomic DNA was isolated 
using a Genomic DNA Purification Kit (Promega, Mad-
ison, WI, USA) and stored at −20°C before use. Geno-
typing was conducted using a Sequenom MassARRAY 
Genotyping Platform (Sequenom, San Diego, CA, USA).
Toxicity evaluation criteria
Platinum-based chemotherapy-induced toxicity was esti-
mated according to the National Cancer Institute Com-
mon Toxicity Criteria, Version 3.0. The toxicity intensity 
was graded on a scale of 1–5 as follows: grade 1, mild 
adverse events; grade 2, moderate adverse events; grade 
3, severe adverse events; grade 4, life-threatening or 
disabling adverse events; and grade 5, death related to 
adverse events. We recruited patients experiencing grade 
0 to grade 4 toxicity, and they were divided into two cat-
egories. Patients experiencing grade 0–2 adverse events 
were classified into the low-toxicity category, whereas 
patients with grades 3 and 4 adverse events were classi-
fied into the severe toxicity category.
Statistical analysis
The genotype frequencies observed among all patients 
were compared with their expected frequencies under 
Hardy–Weinberg equilibrium using a χ2 test (P  >  0.05). 
Sex, age, smoking status, tumor histology, clinical stage, 
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and Eastern Cooperative Oncology Group (ECOG) per-
formance status were considered potential covariates for 
logistic regression. All analyses were performed using 
PLINK (version 1.07, http://pngu.mgh.harvard.edu/pur-
cell/plink/) and SPSS 13.0 software (SPSS Inc, Chicago, 
IL, USA). Odds ratios (OR) and their 95% confidence 
intervals (95% CI) were used to assess the association 
between treatment outcomes and gene polymorphisms. 
P < 0.05 was considered statistically significant.
Results
Patient characteristics
A total of 220 patients who received first-line platinum-
based chemotherapy were recruited for this study. A 
total of 44 SNPs were genotyped in these patients, and 
37 of them were in HWE (P  >  0.05) and exhibited an 
MAF ≥ 5%. The basic information of these SNPs and the 
clinical characteristics of these lung cancer patients are 
summarized in Tables 1 and 2, respectively. Hematologic, 
Table 1 Thirty-seven single nucleotide polymorphisms (SNPs) in DNA mismatch repair (MMR) genes
MLH1 MutL homolog 1, MSH2-6 MutS homolog 2-6, A adenine, T thymine, C cytosine, G guanine, UTR untranslated region, MAF minor allele frequency, HWE Hardy–
Weinberg equilibrium
Gene SNP (rs number) Allele Localization Call rate (%) MAF HWE
MLH1 rs10849 G/A 3′‑UTR 99.55 0.09 0.764
rs1540354 A/T Intron 97.73 0.68 0.635
rs749072 T/C Intron 97.73 0.62 0.217
MSH2 rs10191478 T/G Intron 97.73 0.20 0.264
rs12999145 A/G Intron 98.64 0.53 0.783
rs13019654 G/T Intron 96.82 0.28 0.710
rs1981929 G/A Intron 97.27 0.86 0.309
rs2303428 A/C Intron 98.64 0.33 0.234
rs4608577 T/G Intron 93.18 0.13 0.106
rs4952887 C/T Intron 98.18 0.15 0.124
rs6544991 A/C Intron 95.00 0.36 0.605
rs7602094 T/C Intron 95.91 0.66 0.560
MSH3 rs245340 A/C Intron 97.73 0.24 0.203
rs245346 T/C Intron 97.73 0.45 0.738
rs26778 A/T Intron 96.36 0.59 0.713
rs26784 T/C Intron 97.73 0.37 0.860
rs3816729 A/G Intron 96.36 0.30 0.927
rs6151627 A/G Intron 99.09 0.29 0.554
rs6151670 C/G Intron 98.18 0.28 0.258
rs6151892 T/A Intron 99.09 0.33 0.729
rs6151914 C/T Intron 97.73 0.09 0.065
rs7709909 C/T Intron 99.09 0.31 0.572
MSH4 rs3806162 T/G 5′ near gene 99.09 0.22 0.393
rs5745532 T/C Intron 99.09 0.75 0.112
MSH5 rs3117572 G/A Intron 98.64 0.28 0.103
rs409558 A/G Intron 100.00 0.13 0.312
rs707937 C/G Intron 96.82 0.42 0.369
rs707938 A/G Synonymous 97.27 0.30 0.428
rs707939 G/T Intron 100.00 0.39 0.097
rs805304 C/A 5′ near gene 98.18 0.69 0.448
MSH6 rs2020910 T/A Intron 99.09 0.17 0.893
rs2348244 T/C Intron 99.09 0.39 0.856
rs2710163 T/C Intron 98.18 0.70 0.856
rs3136329 T/C Intron 97.27 0.13 0.108
rs3732190 G/A Intron 95.91 0.09 0.933
rs6713506 G/A Intron 98.64 0.06 0.852
rs6742522 G/A Intron 99.09 0.11 0.259
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gastrointestinal, and overall toxicity were assessed after 
the first two cycles of chemotherapy. Severe overall toxic-
ity occurred in 79 (35.9%) patients. Among them, severe 
hematologic and gastrointestinal toxicity occurred in 55 
(25.0%) and 31 (14.1%) patients, respectively.
Association between MMR gene polymorphisms 
and toxicity
The genotypes of the 37 SNPs in 6 DNA MMR genes 
were determined in the 220 patients. The results are sum-
marized in Additional file 1: Table S1. Six SNPs exhibited 
significant associations with toxicity (Table  3). MSH2 
rs6544991 (OR 2.98, 95% CI 1.20–7.40, P =  0.019) was 
associated with gastrointestinal toxicity in the dominant 
model. MSH3 rs6151627 (OR 2.38, 95% CI 1.23–4.60, 
P  =  0.010), MSH3 rs6151670 (OR 2.05, 95% CI 1.07–
3.93, P = 0.031), and MSH3 rs7709909 (OR 2.38, 95% CI 
1.23–4.64, P = 0.010) were associated with hematologic 
toxicity in the dominant model. MSH5 rs805304 was sig-
nificantly associated with overall toxicity (additive model: 
OR 1.66, 95% CI 1.04–2.65, P = 0.033; dominant model: 
OR 2.21, 95% CI 1.19–4.09, P = 0.012). MSH5 rs707939 
was significantly associated with overall toxicity (additive 
model: OR 0.45, 95% CI 0.28–0.73, P = 0.001; dominant 
model: OR 0.42, 95% CI 0.23–0.76, P = 0.004; recessive 
model: OR 0.27, 95% CI 0.09–0.84, P = 0.023) and gas-
trointestinal toxicity (additive model: OR 0.46, 95% CI 
0.24–0.88, P = 0.020; dominant model: OR 0.44, 95% CI 
0.20–0.96, P = 0.038).
Stratification analyses
Stratification analyses were performed to investigate the 
associations between all SNPs that were significantly 
associated with overall toxicity. Patients were stratified 
by cancer type (squamous cell carcinoma or adenocar-
cinoma), age (≤55  years or >55  years), smoking status 
(non-smoker or smoker), and sex (male or female). As 
shown in Fig.  1, MSH5 rs707939 exhibited significant 
associations with squamous cell carcinoma (additive 
model: OR 0.25, 95% CI 0.12–0.51, P < 0.001; dominant 
model: OR 0.20, 95% CI 0.08–0.46, P  <  0.001; recessive 
model: OR 0.19, 95% CI 0.04–0.88, P =  0.034), patients 
≤55  years of age (additive model: OR 0.50, 95% CI 
0.29–0.85, P = 0.011; dominant model: OR 0.48, 95% CI 
0.25–0.93, P = 0.030), smokers (additive model: OR 0.44, 
95% CI 0.24–0.81, P = 0.009; dominant model: OR 0.37, 
95% CI 0.17–0.80, P = 0.011), and male patients (additive 
model: OR 0.50, 95% CI 0.29–0.85, P = 0.011; dominant 
model: OR 0.48, 95% CI 0.25–0.93, P = 0.030). No signifi-
cant associations were noted for any other SNPs. Taken 
together, these results indicate that T allele carriers of 
MSH5 rs707939 polymorphism have better tolerance to 
gastrointestinal toxicity and overall toxicity than carriers 
of other polymorphisms.
Discussion
In this study, we investigated whether polymorphisms of 
MMR genes (MLH1, MSH2, MSH3, MSH4, MSH5, and 
MSH6) were associated with platinum-based chemo-
therapy toxicity in 220 NSCLC patients. We evaluated 
the associations between these gene polymorphisms and 
gastrointestinal, hematologic, and overall toxicities. Our 
results showed that MSH2 rs6544991 was associated with 
gastrointestinal toxicity, MSH3 rs6151627, rs6151670, 
and rs7709909 were associated with hematologic toxicity, 
and MSH5 rs707939 and rs805304 were associated with 
gastrointestinal toxicity and overall toxicity.
Table 2 The clinical characteristics of  the 220 non-small 
cell lung cancer (NSCLC) patients
ECOG Eastern Cooperative Oncology Group, PS performance status
Variate Number of patients [cases (%)]
Total 220
Age (years)
 ≤55 93 (42.3)
 >55 127 (57.7)
Smoking status
 Never 95 (43.2)
 Ever 125 (56.8)
Gender
 Male 165 (75.0)
 Female 55 (25.0)
ECOG PS
 0–1 39 (17.7)
 2 181 (82.3)
Histological type
 Adenocarcinoma 108 (49.1)
 Squamous cell carcinoma 112 (50.9)
Stage
 I–II 8 (3.6)
 III–IV 212 (96.4)
Platinum‑based drug
 Cisplatin 37(16.8)
 Carboplatin 183 (83.2)
Chemotherapy regimen
 Platinum‑gemcitabine 112 (50.9)
 Platinum‑pemetrexed 68 (30.9)
 Platinum‑paclitaxel 23 (10.4)
 Platinum‑docetaxel 12 (5.5)
 Platinum‑navelbine 5 (2.3)
Severe toxicity
 Total 79 (35.9)
 Hematologic toxicity 55 (25.0)
 Gastrointestinal toxicity 31 (14.1)
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A previous study showed that MSH2 was a key protein 
that influenced 6-thioguanine (6-TG)- and O6-methyl-
guanine-induced toxicity in DNA glycosylase-deficient 
cells, indicating that MSH2 plays an important role in 
attenuating oxidative DNA damage [24]. In our study, 
C allele carriers of rs6544991, which features an A/C 
single-nucleotide variation located in the intron area 
of MSH2, exhibited poor gastrointestinal toxicity toler-
ance after being treated with platinum-based chemo-
therapy. We speculated that this SNP may affect the 
ability of MSH2 to remove platinum adducts. In addi-
tion, our results showed that MSH3 rs6151627 G allele 
carriers, rs6151670 G allele carriers, and rs7709909 T 
allele carriers exhibited poor hematologic toxicity tol-
erance after being treated with platinum-based chemo-
therapy. MSH3 rs6151627 is an A/G single-nucleotide 
variation, rs6151670 is a C/G single-nucleotide varia-
tion, and rs7709909 is a C/T single-nucleotide varia-
tion. All of these polymorphisms are intron variants of 
MSH3. Methylation of the MSH3 promoter is involved 
in esophageal tumorigenesis, suggesting that it plays an 
important role in modulating cell chemosensitivity. As 
a DNA MMR gene, MSH3 forms the MutSβ heterodu-
plex with MSH2. The MSH2/MSH3 heterodimer is an 
ATPase that plays a critical role in mismatch recogni-
tion and repair initiation. It binds to DNA mismatches 
by recognizing 2- to 13-bp insertion-deletion loops [30]. 
The three SNPs are speculated to affect the function 
of MSH3; however, the underlying mechanism is still 
unclear.
Another important finding of our study was that MSH5 
polymorphisms were significantly related to overall tox-
icity. MSH5 rs707939 T allele carriers exhibited better 
gastrointestinal and overall toxicity tolerance after being 
treated with platinum-based chemotherapy. Moreover, 
among MSH5 rs707939 T allele carriers, stratification 
analysis showed that male patients, patients ≤55  years 
old, smokers, and patients diagnosed with squamous 
cell carcinoma faced a lower risk of overall severe toxic-
ity than their counterparts. All these results indicated 
that MSH5 rs707939 was associated with reduced cis-
platin-induced gastrointestinal and overall toxicities in 
NSCLC patients. In addition, MSH5 rs805304 was also 
significantly associated with gastrointestinal and over-
all toxicities. It is noteworthy that rs707939 is a G/T 
single-nucleotide variation in the intron of MSH5. Previ-
ous studies suggested that mutations in MSH5 result in 
alkylation tolerance in mammalian cells, which is associ-
ated with lung cancer risk [26, 31]. Thus, rs707939 and 
rs805304 may also affect MSH5 activity.
As far as we know, DNA MMR gene defects lead to 
MMR function loss, which increases the spontaneous 
Table 3 Associations between MMR gene polymorphisms and platinum-based chemotherapy toxicity in the 220 NSCLC 
patients
OR odds ratio, 95% CI 95% confidence interval; other abbreviations as in Table 1
Toxicity Gene SNP Additive model Dominant model Recessive model
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Overall MSH2 rs6544991 1.18 (0.77–1.79) 0.447 1.39 (0.76–2.55) 0.290 1.02 (0.44–2.33) 0.973
MSH3 rs6151627 1.20 (0.77–1.86) 0.419 1.49 (0.83–2.65) 0.181 0.77 (0.27–2.17) 0.618
rs6151670 1.14 (0.73–1.76) 0.572 1.37 (0.76–2.45) 0.293 0.75 (0.27–2.13) 0.593
rs7709909 1.21 (0.79–1.87) 0.380 1.51 (0.84–2.71) 0.163 0.83 (0.31–2.19) 0.703
MSH5 rs707939 0.45 (0.28–0.73) 0.001 0.42 (0.23–0.76) 0.004 0.27 (0.09–0.84) 0.023
rs805304 1.66 (1.04–2.65) 0.034 2.21 (1.19–4.09) 0.012 1.21 (0.44–3.34) 0.716
Hematologic MSH2 rs6544991 1.01 (0.64–1.61) 0.957 0.97 (0.50–1.87) 0.919 1.12 (0.45–2.77) 0.805
MSH3 rs6151627 1.55 (0.96–2.50) 0.074 2.38 (1.23–4.60) 0.010 0.75 (0.23–2.44) 0.635
rs6151670 1.42 (0.88–2.29) 0.153 2.05 (1.07–3.93) 0.032 0.75 (0.23–2.43) 0.630
rs7709909 1.55 (0.97–2.49) 0.067 2.38 (1.23–4.64) 0.010 0.87 (0.30–2.58) 0.808
MSH5 rs707939 0.68 (0.41–1.12) 0.128 0.66 (0.35–1.28) 0.219 0.50 (0.16–1.54) 0.225
rs805304 1.37 (0.83–2.27) 0.223 1.99 (1.01–3.90) 0.047 0.60 (0.16–2.20) 0.436
Gastrointestinal MSH2 rs6544991 1.56 (0.90–2.69) 0.113 2.98 (1.20–7.40) 0.019 0.88 (0.28–2.76) 0.827
MSH3 rs6151627 0.63 (0.33–1.20) 0.161 0.54 (0.24–1.19) 0.128 0.66 (0.14–3.02) 0.592
rs6151670 0.67 (0.35–1.27) 0.220 0.59 (0.27–1.32) 0.199 0.64 (0.14–2.94) 0.568
rs7709909 0.62 (0.33–1.18) 0.145 0.55 (0.25–1.20) 0.132 0.58 (0.13–2.63) 0.481
MSH5 rs707939 0.46 (0.24–0.88) 0.020 0.44 (0.20–0.96) 0.038 0.21 (0.03–1.65) 0.139
rs805304 1.64 (0.90–2.97) 0.105 1.86 (0.83–4.20) 0.133 1.85 (0.56–6.14) 0.314
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mutation frequencies of cells. Cell mutation phenotypes 
are thought to result in malignant transformation and 
cause continuous accumulation of gene mutation events. 
Many error messages across the entire genome eventu-
ally affect the effectiveness and toxicity of chemother-
apy. However, the detailed mechanisms underlying the 
effects of these SNPs on gene function need to be studied 
further.
Conclusions
Our findings indicate that carriers of the MSH5 rs707939 
T allele, the MSH2 rs6544991 C allele, the MSH3 
rs6151627 and rs6151670 G alleles, and the MSH3 
rs7709909 T allele have poor toxicity tolerance. There-
fore, these polymorphisms are potential clinical markers 
for predicting platinum-based chemotherapy toxicity in 
Chinese NSCLC patients. However, a study with a larger 
sample size is needed to validate these findings in the 
future.
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